Morgan Stanley
PRME icon

Morgan Stanley’s Prime Medicine PRME Stock Holding History

Morgan Stanley’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.62M Buy
708,963
+69,506
+11% +$231K ﹤0.01% 4686
2026
Q1 		$2.23M Sell
639,457
-530,441
-45% -$2.02M ﹤0.01% 4700
2025
Q4 		$4.06M Buy
1,169,898
+438,894
+60% +$1.95M ﹤0.01% 4340
2025
Q3 		$4.05M Buy
731,004
+143,328
+24% +$582K ﹤0.01% 4318
2025
Q2 		$1.45M Buy
587,676
+232,500
+65% +$358K ﹤0.01% 4906
2025
Q1 		$707K Buy
355,176
+43,900
+14% +$112K ﹤0.01% 5173
2024
Q4 		$909K Buy
311,276
+10,885
+4% +$38.2K ﹤0.01% 5142
2024
Q3 		$1.16M Buy
300,391
+116,426
+63% +$539K ﹤0.01% 4963
2024
Q2 		$946K Sell
183,965
-14,501
-7% -$87.9K ﹤0.01% 4993
2024
Q1 		$1.39M Sell
198,466
-13,268
-6% -$101K ﹤0.01% 4788
2023
Q4 		$1.88M Buy
211,734
+168,943
+395% +$1.3M ﹤0.01% 4547
2023
Q3 		$408K Sell
42,791
-15,138
-26% -$197K ﹤0.01% 5256
2023
Q2 		$849K Buy
57,929
+24,544
+74% +$343K ﹤0.01% 4928
2023
Q1 		$411K Buy
33,385
+12,996
+64% +$212K ﹤0.01% 5366
2022
Q4 		$379K Buy
+20,389
New +$368K ﹤0.01% 5378

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Morgan Stanley's PRME Position: Q2 2026 in Review

Morgan Stanley increased its Prime Medicine (PRME) stake by 11% in Q2 2026, buying an estimated $231K and bringing the position to 708,963 shares worth $2.62M. The position accounts for ﹤0.01% of the portfolio, ranked #4686.

Morgan Stanley first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $4.06M in Q4 2025. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Morgan Stanley held 708,963 shares of Prime Medicine worth $2.62M as of Q2 2026.
  • Morgan Stanley bought 69,506 Prime Medicine shares in Q2 2026, an estimated $231K.
  • Prime Medicine made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #4686 holding.
  • Morgan Stanley first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Morgan Stanley's Prime Medicine position peaked at $4.06M in Q4 2025.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.